nCounter® PanCancer Immune Profiling Panel

Helping Your Research

Gene expression profiling can be challenging because reproducibility and data analysis can be extremely demanding. The nCounter PanCancer Immune Profiling Panel offers fast and high-throughput multiplex gene expression analysis solution for human or mouse genes. Each panel comes with 770 genes from 13 cancer-associated canonical pathways to support the understanding of basic cancer biology.

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

How It Works

Perform multiplex gene expression analysis in human or mouse with 770 genes from 14 different immune cell types, common checkpoint inhibitors, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinically actionable gene expression profiles in the context of cancer immunotherapy.

01:

Comprehensive profiling of the immune response optimized for immuno-oncology research

02:

Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment

03:

Profile the expression of 30 CT antigens in humans

04:

Assess mechanistic pathway activity for single or combination studies

05:

Customizable with up to 55 additional user-defined genes with Panel Plus option

06:

Multi-analyte analysis with Vantage 3D™ Assays

The nCounter PanCancer Immune Profiling Panel is for cancer researchers that need more markers than is practical for RT-qPCR but don’t want the broad approach that next-gen sequencing (NGS) offers. The Panel is fully compatible with clinically relevant sample types such as fresh-frozen (FF) tissue, formalin-fixed, paraffin-embedded (FFPE) tumor sections, isolated immune cell populations such as PBMCs, and cell lysates. The panel may be used in conjunction with nCounter Panel Plus products for additional flexibility in experimental design.

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Immune Cell Type Gene Coverage

Product Specifications

Product Comparison

Immune Cell Type Gene Coverage

Product Specifications

Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

View All Related Resources

Whitepaper PanCancer Immune Profiling Advanced Analysis – Whitepaper

Product Bulletin Hallmarks of Cancer – Product Bulletin

Whitepaper Multiplexed Cancer Immune Response Analysis – Whitepaper

Publications

View All Publications

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.

Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.

Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.